Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel arGEN-X BRU:ARGX.BL, NL0010832176

  • 366,100 12 aug 2022 17:38
  • +1,500 (+0,41%) Dagrange 360,700 - 378,200
  • 111.671 Gem. (3M) 80,9K

Argenx stoomt richting eerste medicijn op de markt

1.869 Posts
Pagina: «« 1 ... 28 29 30 31 32 ... 94 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 1 februari 2021 14:43
    quote:

    Shockerdj schreef op 1 februari 2021 14:40:

    Vergeef mij als ik in herhaling val, maar kan iemand kort uitleggen waarom de verschillende koersdoelen een stuk lager liggen als de huidige waarde? Ondanks men " kopen " adviseert?
    Dat moet je aan de analisten vragen.
  2. Pokerface 1 februari 2021 17:04
    Vergeet niet dat er dit jaar mogelijk een blockbustermedicijn goedgekeurd gaat worden. En dan hebben we het over slecht 1 indicatie terwijl er nog meerdere onderzoeken lopen en er nog eentje aangekondigd gaat worden. En dan hebben we het dus alleen over Efgartigimod. Er zit veel fantasie in het aandeel, dat geef ik toe.
  3. Detex 1 februari 2021 22:47
    argenx announces launch of proposed global offering

    ARGNF

    0.00%

    More content below

    ARGX

    +8.32%

    More content below

    argenx SE

    Updated Mon, February 1, 2021, 10:03 PM

    ARGNF

    0.00%

    More content below

    ARGX

    +8.32%

    More content below

    Regulated information — Inside information

    February 1, 2021

    Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced today that it has commenced a global offering of $750 million (approximately €618 million) of ordinary shares, which may be represented by American Depository Shares (“ADSs”). The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the United Kingdom. Each of the ADSs represents the right to receive one ordinary share, nominal value of €0.10 per share. The U.S. offering and the European private placement are expected to close simultaneously.

    In addition, argenx intends to grant the underwriters of the offering a 30-day option to purchase additional ordinary shares (which may be represented by ADSs) in an aggregate amount of up to 15% of the total number of ordinary shares (including represented by ADSs) proposed to be sold in the offering, on the same terms and conditions.

    Baillie Gifford Overseas Limited and entities affiliated with it have indicated an interest in purchasing an aggregate of up to $415 million (approximately €342 million) of ordinary shares in this offering at the offering price per share and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no ordinary shares to these potential purchasers, and these potential purchasers could determine to purchase more, fewer or no shares in this offering.

    argenx’s ADSs are currently listed on the Nasdaq Global Select Market under the symbol “ARGX.” and argenx’s ordinary shares are currently listed on Euronext Brussels under the symbol “ARGX.”.

1.869 Posts
Pagina: «« 1 ... 28 29 30 31 32 ... 94 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

arGEN-X Meer »

Koers 366,100   Verschil +1,50 (+0,41%)
Laag 360,700   Volume 111.671
Hoog 378,200   Gem. Volume 80.921
12 aug 2022 17:38
Premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links